Dutch Startup Secures €1.67 Million to Make Hospital-Grade Heart Tests Available Anywhere
Netherlands, Saturday, 18 April 2026.
HeartEye’s breakthrough technology transforms complex 12-channel ECG recordings from a time-intensive hospital procedure requiring trained professionals into a simple one-minute test that can be performed by general practitioners, assistants, or nurses anywhere. The Dutch medtech company raised €1.675 million from ROM InWest and prominent tech investors to accelerate market introduction of their wireless ECG recorder. This innovation promises to detect heart conditions earlier while reducing unnecessary hospital referrals, potentially saving lives and cutting healthcare costs through improved accessibility to professional cardiac diagnostics.
Healthtech Innovation Addresses Critical Healthcare Gap
This development represents a significant advancement in healthtech, specifically targeting cardiovascular diagnostics through mobile medical technology. HeartEye’s innovation addresses a fundamental challenge in healthcare delivery: bringing sophisticated diagnostic capabilities from hospital settings to primary care environments and eventually to patients’ homes [1]. The company’s patented mobile 12-channel ECG recorder transforms what is currently a time-consuming and complex process requiring trained professionals into a streamlined procedure that takes less than one minute [1]. Traditional 12-channel ECG recordings remain confined to hospital environments due to their complexity and the specialized training required to operate the equipment effectively [GPT].
How the Revolutionary ECG Technology Works
HeartEye’s fully wireless ECG recorder operates as a handheld, user-friendly device that enables general practitioners, assistants, or nurses to create 12-channel ECGs in under one minute [1]. The system integrates with a digital platform that allows healthcare providers to share heart recordings with doctors or specialists for interpretation and diagnostic support [1]. This technology brings hospital-grade cardiac diagnostics closer to patients by eliminating the traditional barriers of location and specialized equipment [1]. The device’s portability and ease of use enable healthcare providers in general practice offices and nursing homes to perform professional-quality cardiac diagnostics that were previously only available in hospital settings [1]. Long-term plans include enabling patients to conduct these tests independently at home, further expanding access to cardiac monitoring [1].
Strategic Investment and Market Positioning
The €1.675 million funding round was led by ROM InWest, with participation from notable technology industry figures including Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas [1]. Health Innovations joined as a returning investor, marking their second investment in the company [1]. ROM InWest specifically identified HeartEye as filling a crucial gap in the venture capital ecosystem, noting that most VC firms either invest during prototype development or after CE certification and market introduction, leaving companies vulnerable during the intensive regulatory certification period [1]. The investment addresses this challenge by supporting HeartEye through the capital-intensive phase of establishing production processes and obtaining Medical Device Regulation (MDR) certification [1].
Clinical Development and Market Impact Strategy
The funding will enable HeartEye to conduct pivotal clinical studies while advancing their AI software development and expanding production capacity to meet anticipated demand following market authorization [1]. During the current regulatory phase, the product cannot be used clinically and generates no regular revenue, despite requiring substantial investments in certification processes [1]. HeartEye’s technology promises dual benefits: earlier detection of heart conditions ensuring appropriate patients reach cardiologists promptly, while preventing unnecessary hospital referrals for patients who don’t require specialized care [1]. This approach contributes to more efficient healthcare delivery, reduced costs, and decreased workload pressure on healthcare systems [1]. ROM InWest anticipates that HeartEye’s innovative ECG recorder will enable the company to grow into a leading player that stimulates high-quality employment and knowledge development regionally while making a direct and sustainable contribution to the future sustainability and affordability of healthcare [1].